Save time and jump to the most important pieces.
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
3 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
10-Q - TALPHERA, INC. (0001427925) (Filer)
8-K - TALPHERA, INC. (0001427925) (Filer)
8-K - TALPHERA, INC. (0001427925) (Filer)
Five sites actively screening with multiple patients having completed the study; two additional institutions expected to begin screening in the fourth quarter totaling seven active sites Cash and investments at September 30, 2024 of $11.1 million Conference call and webcast to be held Wednesday, November 13, 2024 at 4:30 pm ET SAN MATEO, Calif., Nov. 13, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced third quarter 2024 financial results and provided a corporate update. "Our NEPHRO CRRT study has gained momentu
SAN MATEO, Calif., Nov. 6, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2024 financial results after market close on Wednesday, November 13, 2024, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast
NEPHRO CRRT study patient screening has initiated at multiple clinical sites The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational study in 166 patients at up to 14 clinical sites Cash and investments at June 30, 2024 of $14.0 million Conference call and webcast to be held Wednesday, August 14, 2024 at 4:30 pm ET SAN MATEO, Calif., Aug. 14, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced second quarter 2024 financial results and provided a corporate update. "We're excite
Gainers Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 68.1% to $1.0 during Thursday's after-market session. The market value of their outstanding shares is at $13.3 million. Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 15.67% to $0.32. The market value of their outstanding shares is at $17.5 million. Talphera (NASDAQ:TLPH) shares rose 12.64% to $0.92. The market value of their outstanding shares is at $15.6 million. Helius Medical Tech (NASDAQ:HSDT) shares moved upwards by 10.11% to $1.06. The market value of their outstanding shares is at $3.1 million. Clover Health Investments (NASDAQ:CLOV) stock rose 9.72% to $1.13. The company's market cap stands at $561.0 mil
Gainers Nexalin Technology (NASDAQ:NXL) stock increased by 48.1% to $1.54 during Wednesday's after-market session. The company's market cap stands at $11.4 million. Tempest Therapeutics (NASDAQ:TPST) stock moved upwards by 40.0% to $3.99. The market value of their outstanding shares is at $88.6 million. ASLAN Pharma (NASDAQ:ASLN) stock increased by 18.51% to $0.37. The market value of their outstanding shares is at $8.3 million. Talphera (NASDAQ:TLPH) shares increased by 15.18% to $0.9. The company's market cap stands at $15.2 million. Geovax Labs (NASDAQ:GOVX) stock rose 13.15% to $2.15. The market value of their outstanding shares is at $5.4 million. SAB Biotherapeutics (NASDAQ:SABS)
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive
Five sites actively screening with multiple patients having completed the study; two additional institutions expected to begin screening in the fourth quarter totaling seven active sites Cash and investments at September 30, 2024 of $11.1 million Conference call and webcast to be held Wednesday, November 13, 2024 at 4:30 pm ET SAN MATEO, Calif., Nov. 13, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced third quarter 2024 financial results and provided a corporate update. "Our NEPHRO CRRT study has gained momentu
SAN MATEO, Calif., Nov. 6, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2024 financial results after market close on Wednesday, November 13, 2024, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast